Floatz logo

Bempegaldesleukin

Urothelial Carcinoma

Nektar Therapeuticsprotein_peptidePhase 1/2Dormant
C
38/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
26/ 100
Competitive Position
73/ 100

Competitive context

86 Active assets in the Urothelial Carcinoma cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
Beijing Biotech
Phase 3BB
Pembrolizumab
Sutro Biopharma, Inc.
Phase 3BB
Epirubicin
Sutro Biopharma, Inc.
Phase 3BB
CIS-DIAMMINEDICHLOROPLATINUM II
Nagoya University
Phase 3BB
Docetaxel
NuCana plc
Phase 3BB

View all 50 →

Same molecule, other indications

Bempegaldesleukin is also rated in:

melanomaDormant
CC
Indicative ·
46 / 100
View asset →
cutaneous melanomaDormant
CC
Indicative ·
46 / 100
View asset →
renal cell carcinomaDormant
CC
Indicative ·
45 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →